A study of intranasal remifentanil for intubation and surfactant administration in newborns
Intranasal remifentanil for pain management during intubation and surfactant administration in premature newborns – a randomised double blind controlled pilot study of efficacy
Associate Professor Ian Wright
40 participants
Jul 1, 2012
Interventional
Conditions
Summary
The primary purpose of this study is to determine the efficacy of intranasal remifentanil for improving intubating conditions in neonates requiring the INSURE procedure as part of their medical care. Usual pain management (comfort/environmental measures and age/weight-appropriate sucrose) will be provided to all neonates.
Eligibility
Inclusion Criteria3
- Born at John Hunter Childrens Hospital and transferred to Neonatal Intensive Care Unit.
- Require the INSURE procedure as part of their medical care.
- Are 28–44 weeks post-conceptional age at the time of the procedure.
Exclusion Criteria5
- Need for urgent intubation for resuscitation.
- Major congenital anomalies likely to influence reliability of the primary outcome measure.
- Severe neurological obtundation.
- Current clinical seizures.
- Concomitant muscle relaxant.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Prior to the intubation surfactant extubation (INSURE) procedure, babies will receive standard care plus intranasal remifentanil 2 micrograms/kg.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000386831